Metrics to compare | 191420 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship191420PeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.8x | −6.9x | −0.4x | |
PEG Ratio | 0.01 | −0.08 | 0.00 | |
Price/Book | 1.4x | 1.9x | 2.6x | |
Price / LTM Sales | 9.9x | 6.9x | 3.1x | |
Upside (Analyst Target) | - | 73.3% | 49.0% | |
Fair Value Upside | Unlock | 27.0% | 7.1% | Unlock |
TegoScience Inc., a biotechnology-based cosmetics company, engages in the production of various skin cell therapy products originating from human epithelial cells in South Korea. The company offers Holoderm, a commercialized cultured skin autograft; Kaloderm, an allogeneic cell therapy product for healing wounds; Rosmir, a fibroblast cell therapy; and Neoderm, a three-dimensionally cultured skin model. It also provides KCM for skin regeneration effect; Chemotide, a single-chain human peptide; contract research services, such as biologics quality control services and histology services; and SkinBank, an insurance for cells, as well as engages in cell therapy business. The company was founded in 2001 and is headquartered in Seoul, South Korea.